As it has been proposed that combinatorial marker panel will out-perform any single marker for prognostic predictions27,28, we propose that RDM1 can serve as an additional marker to the marker panel for the diagnosis and/or stratification for clinical management of lung adenocarcinoma. This evidence concerns the gene RDM1 and lung adenocarcinoma.